Invesco Ltd. Sarepta Therapeutics, Inc. Transaction History

Invesco Ltd.

$600 Billion
Q3 2025

A detailed history of Invesco Ltd. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 832,638 shares of SRPT stock, worth $15.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

832,638

Previous 243,481 241.97%

Holding current value

$15.7 Million

Previous $4.16 Million 285.4%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$11.93 - $21.97 $7.03 Million - $12.9 Million	589,157 Added 241.97%	832,638 $16 Million
Q2 2025 Aug 13, 2025	BUY	$17.1 - $63.66 $653,904 - $2.43 Million	38,240 Added 18.63%	243,481 $4.16 Million
Q1 2025 May 12, 2025	SELL	$63.82 - $127.89 $3.83 Million - $7.68 Million	-60,058 Reduced 22.64%	205,241 $13.1 Million
Q4 2024 Feb 13, 2025	SELL	$104.54 - $137.94 $22.7 Million - $29.9 Million	-216,862 Reduced 44.98%	265,299 $32.3 Million
Q3 2024 Nov 12, 2024	BUY	$124.33 - $156.75 $12.7 Million - $16 Million	101,784 Added 26.76%	482,161 $60.2 Million

Q2 2024 Aug 13, 2024	BUY	$113.33 - $163.85 $31.2 Million - $45.1 Million	275,414 Added 262.39%	380,377 $60.1 Million
Q1 2024 May 14, 2024	BUY	$93.7 - $141.53 $3.4 Million - $5.13 Million	36,268 Added 52.8%	104,963 $13.6 Million
Q4 2023 Feb 12, 2024	SELL	$67.31 - $124.76 $7.14 Million - $13.2 Million	-106,042 Reduced 60.69%	68,695 $6.62 Million
Q3 2023 Nov 13, 2023	SELL	$102.5 - $123.59 $17.1 Million - $20.6 Million	-166,813 Reduced 48.84%	174,737 $21.2 Million
Q2 2023 Aug 11, 2023	SELL	$106.4 - $157.19 $323,775 - $478,329	-3,043 Reduced 0.88%	341,550 $39.1 Million
Q1 2023 May 12, 2023	BUY	$117.53 - $155.99 $14.5 Million - $19.3 Million	123,722 Added 56.02%	344,593 $47.5 Million
Q4 2022 Feb 13, 2023	BUY	$100.86 - $132.13 $4.75 Million - $6.23 Million	47,121 Added 27.12%	220,871 $28.6 Million
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $1.83 Million - $2.88 Million	24,192 Added 16.18%	173,750 $19.2 Million
Q2 2022 Aug 15, 2022	BUY	$62.69 - $88.44 $5.55 Million - $7.83 Million	88,552 Added 145.15%	149,558 $11.2 Million
Q1 2022 May 16, 2022	BUY	$63.15 - $90.42 $141,013 - $201,907	2,233 Added 3.8%	61,006 $4.77 Million
Q4 2021 Feb 14, 2022	SELL	$77.28 - $99.42 $4.52 Million - $5.82 Million	-58,532 Reduced 49.9%	58,773 $5.29 Million
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $859,325 - $1.2 Million	13,026 Added 12.49%	117,305 $10.8 Million
Q2 2021 Aug 17, 2021	BUY	$69.38 - $86.75 $602,287 - $753,076	8,681 Added 9.08%	104,279 $8.11 Million
Q1 2021 May 17, 2021	SELL	$72.25 - $168.95 $97.2 Million - $227 Million	-1,345,786 Reduced 93.37%	95,598 $7.13 Million
Q4 2020 Feb 16, 2021	BUY	$125.56 - $178.74 $43.5 Million - $61.9 Million	346,424 Added 31.64%	1,441,384 $246 Million
Q3 2020 Nov 16, 2020	SELL	$127.12 - $172.34 $9.72 Million - $13.2 Million	-76,434 Reduced 6.53%	1,094,960 $154 Million
Q2 2020 Aug 14, 2020	SELL	$93.0 - $171.7 $35.6 Million - $65.8 Million	-383,275 Reduced 24.65%	1,171,394 $188 Million
Q1 2020 May 15, 2020	SELL	$82.38 - $131.64 $20.6 Million - $32.9 Million	-250,184 Reduced 13.86%	1,554,669 $152 Million
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $1.08 Million - $1.92 Million	-14,173 Reduced 0.78%	1,804,853 $233 Million
Q3 2019 Nov 14, 2019	BUY	$72.81 - $156.91 $2.07 Million - $4.45 Million	28,386 Added 1.59%	1,819,026 $137 Million
Q2 2019 Aug 14, 2019	BUY	$112.21 - $151.95 $85.2 Million - $115 Million	758,888 Added 73.55%	1,790,640 $272 Million
Q1 2019 May 15, 2019	BUY	$106.67 - $151.68 $5.88 Million - $8.36 Million	55,101 Added 5.64%	1,031,752 $123 Million
Q4 2018 Feb 14, 2019	BUY	$97.32 - $148.76 $95 Million - $145 Million	976,651 New	976,651 $107 Million

Others Institutions Holding SRPT

# of Institutions

406

Shares Held

83.7M

Call Options Held

5.27M

Put Options Held

5.94M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $1.65B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account